All Oncology News

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.

Patients with metastatic myxoid/round cell liposarcoma or synovial sarcoma expressing NY-ESO-1 and HLA achieved an ORR of 42% with lete-cel.

The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

More than a dozen teams to share advances in blood cancer treatment and research innovations at the 2024 ASH Annual Meeting.

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Alan P. Venook, MD, highlights notable NCCN guideline updates in HCC, considerations for implementing the changes in the clinic, and next steps in HCC.

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice.

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program has received a grant from the NIH to further investigate the role of RNA and the formation of liquid droplet structures within cancer cells.

The NMPA has approved belzutifan for von Hippel-Lindau disease in RCC, CNS hemangioblastomas, or pNETs not requiring immediate surgery.

A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.

Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.

James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.

Treatment with afami-cel was associated with long-term persistence in the periphery that led to clinical benefit in patients with synovial sarcoma.

Whitney Goldsberry, MD, discusses patient characteristics and disease factors that sway the decision between available PARP inhibitors in ovarian cancer.

Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.

NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.